Published in PLoS One on August 04, 2011
Retracted The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int (2015) 1.40
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int (2014) 1.15
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology (2012) 1.08
Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol (2016) 0.82
IFN-α inhibits telomerase in human CD8⁺ T cells by both hTERT downregulation and induction of p38 MAPK signaling. J Immunol (2013) 0.81
IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am (2012) 0.81
Telomere length dynamics in human memory T cells specific for viruses causing acute or latent infections. Immun Ageing (2013) 0.76
FcγRIIB prevents inflammatory type I IFN production from plasmacytoid dendritic cells during a viral memory response. J Immunol (2015) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev (2005) 15.19
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Obesity, cigarette smoking, and telomere length in women. Lancet (2005) 8.59
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science (2007) 6.33
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol (2008) 5.61
Telomeres and aging. Physiol Rev (2008) 4.79
Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc (2006) 4.00
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci U S A (1995) 2.77
Telomeres in T and B cells. Nat Rev Immunol (2002) 2.76
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study. PLoS One (2010) 2.10
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol (2009) 1.71
Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med (2004) 1.71
Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing (2008) 1.57
High cytotoxic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals. J Immunol (2006) 1.55
Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J Leukoc Biol (2008) 1.40
Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta (2009) 1.37
Factors impacting human telomere homeostasis and age-related disease. Mech Ageing Dev (2007) 1.28
Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology (1999) 1.21
Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood (2000) 1.17
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Telomere length and obesity. Acta Paediatr (2008) 1.10
Weight loss in obese men is associated with increased telomere length and decreased abasic sites in rectal mucosa. Rejuvenation Res (2009) 1.05
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
Telomere and adaptive immunity. Mech Ageing Dev (2007) 1.02
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection (2008) 0.99
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol (2010) 0.95
CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol (2010) 0.93
Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy. J Clin Immunol (2004) 0.91
The emerging role of telomere biology in cardiovascular disease. Front Biosci (Landmark Ed) (2010) 0.89
Merging models of hepatitis C virus pathogenesis. Semin Liver Dis (2005) 0.85
Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat (1996) 0.83
The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis. J Interferon Res (1986) 0.82
T cell renewal rates, telomerase, and telomere length shortening. J Immunol (1998) 0.80
Alpha interferon treatment of chronic hepatitis C. Biomed Pharmacother (1995) 0.77
Interferon-beta1b for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol (2008) 0.77
Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C. J Med Virol (1999) 0.76
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis (2002) 4.69
Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis (2002) 4.67
Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol (2002) 4.62
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis (2004) 3.68
Spatial and temporal clustering of dengue virus transmission in Thai villages. PLoS Med (2008) 3.59
Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet (2007) 3.52
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis (2011) 2.78
Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis (2005) 2.78
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med (2009) 2.59
Dose-related effects of smallpox vaccine. N Engl J Med (2002) 2.55
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol (2002) 2.34
Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. Trop Med Int Health (2008) 2.20
Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev (2008) 2.19
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Dengue--how best to classify it. Clin Infect Dis (2011) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis (2010) 2.00
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J (2007) 1.97
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, 1994-2005. Clin Infect Dis (2010) 1.89
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS One (2009) 1.82
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med (2003) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol (2005) 1.74
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Prediction of dengue disease severity among pediatric Thai patients using early clinical laboratory indicators. PLoS Negl Trop Dis (2010) 1.71
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology (2010) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. J Infect Dis (2002) 1.68
Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J Virol (2003) 1.65
T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol (2002) 1.62
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 1.59
Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol (2006) 1.57
Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever. J Virol (2006) 1.56
Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages. J Infect Dis (2012) 1.55
Fine scale spatiotemporal clustering of dengue virus transmission in children and Aedes aegypti in rural Thai villages. PLoS Negl Trop Dis (2012) 1.53
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.51
IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J Immunol (2002) 1.48
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.43
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis (2004) 1.42
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology (2010) 1.38
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. J Med Virol (2002) 1.37
Drug-induced liver injury associated with statins. Semin Liver Dis (2009) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
Microevolution of Dengue viruses circulating among primary school children in Kamphaeng Phet, Thailand. J Virol (2008) 1.31
Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge. J Virol (2002) 1.29